From Our Partners
Saturday, June 25, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Medical Countermeasures

U.S. Purchases 600,000 Courses of Eli Lilly Monoclonal Antibody That Works Against Omicron

by Global Biodefense Staff
February 10, 2022
U.S. Purchases 600,000 Courses of Eli Lilly Monoclonal Antibody That Works Against Omicron

U.S. Air Force Staff Sgt. Bradley Gorman, a medical technician assigned to a medical augmentation team deployed to Yuma, Arizona, prepares a saline solution while administering monoclonal antibody treatment therapy to a patient at Yuma Regional Medical Center in Yuma, Jan. 4, 2022. The U.S. Air Force Airmen are deployed in support of continued Department of Defense COVID response operations to help communities in need. Credit: Richard Barnes

The U.S. Department of Health and Human Services (HHS) announced on Feb 10. it will acquire 600,000 treatment courses of bebtelovimab, a new monoclonal antibody (mAb) treatment that data shows works against the Omicron variant. The new mAB treatment is manufactured by Eli Lilly and Company, and if it receives emergency use authorization (EUA) by the U.S. Food and Drug Administration, HHS will make the treatment available to states free of charge.

HHS would receive approximately 300,000 treatment courses of this monoclonal antibody in February and approximately 300,000 treatment courses in March. Recently, it was determined that data shows that two monoclonal antibody treatments – one made by Lilly (bamlanivimab/etesevimab), and one made by Regeneron (REGEN-COV) – are highly unlikely to work against Omicron, which currently is estimated to make up about 100 percent of all COVID-19 cases in the U.S. Early data suggests that this new product by Lilly has activity against both Omicron and the BA.2 Omicron subvariant.

“If authorized by FDA, this purchase will add an additional 600,000 courses of treatment to our nation’s ‘medicine cabinet’ that could help prevent severe outcomes for Americans who do get sick with COVID-19.,” noted HHS Secretary Xavier Becerra. “Our top priority is preventing people from getting sick in the first place, which is why it is critical that Americans continue to get vaccinated and get their booster shot as soon as they’re eligible.”

The contract also includes a future option for 500,000 more doses and was awarded as a result of collaboration between the HHS Office of the Assistant Secretary for Preparedness and Response (ASPR) and the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND).

Source: HHS

Related: FDA Authorizes New Monoclonal Antibody for Treatment of COVID-19 that Retains Activity Against Omicron Variant Feb 11, 2022

From Our Partners
Tags: ASPRAwardsCoronavirusCOVID CountermeasuresCOVID-19Editor PickEUAHHSJPEO-CBRNDSARS-CoV-2Therapeutic Antibodies

Related Posts

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control
Medical Countermeasures

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine
Medical Countermeasures

Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine

May 30, 2022
Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors
Industry News

Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors

May 26, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC